Asahi Kasei以9.21亿美元的价格购买德国生物技术Aicuris, 提升其在移植和传染性疾病方面的专业药房重点。 Asahi Kasei to acquire German biotech Aicuris for $921 million, boosting its specialty pharma focus in transplant and infectious diseases.

Asahi Kasei同意以7.8亿欧元(约9.21亿美元)的价格收购德国的Aicuris生物制药公司Aicuris,预计于2026年初结束交易。 Asahi Kasei has agreed to acquire German biopharmaceutical company Aicuris for 780 million euros, or about $921 million, with the deal expected to close in early 2026. 收购加强了Asahi Kasei的专科制药平台,特别是在治疗移植和免疫杂乱患者的严重感染方面。 The acquisition strengthens Asahi Kasei’s specialty pharmaceutical platform, particularly in treating severe infections in transplant and immunocompromised patients. Aicuris带来了三个主要资产:Prepymis,一种在移植接受者中预防细胞瘤病毒的药物;pritilivir,在晚期试验中进行口服类疹治疗,预期林业发展局将于2026年批准;AIC468,肾移植病人BK病毒实验疗法。 Aicuris brings three key assets: Prevymis, a drug for preventing cytomegalovirus in transplant recipients; pritelivir, an oral herpes treatment in late-stage trials with expected FDA approval in 2026; and AIC468, an experimental therapy for BK virus in kidney transplant patients. 该协议支持阿萨希·开赛扩大其在移植、肾病学和传染病方面的全球存在的战略,目标是到2030年实现3 000亿日元的药品销售和15%的营业比值。 The deal supports Asahi Kasei’s strategy to expand its global presence in transplant, nephrology, and infectious diseases, with the goal of achieving 300 billion yen in pharmaceutical sales and a 15% operating margin by 2030.